Navigation Links
Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
Date:4/1/2008

SAN DIEGO, April 1, 2008 /PRNewswire-FirstCall/ -- Cardium Therapeutics (Amex: CXM) and its operating unit InnerCool Therapies announced today that InnerCool has entered into a European commercialization agreement with Euromed Medizinisch GmbH (Euromed), a leading distributor of cardiology medical products. Under the terms of the agreement, Euromed will have exclusive marketing, sales and distribution rights in Austria, Germany and Switzerland for InnerCool's portfolio of temperature modulation systems. This agreement covers InnerCool's CoolBlue(TM), a nurse-friendly and cost-effective surface cooling temperature modulation system, which was launched in the U.S. market during the fourth quarter 2007, as well as InnerCool's, premium-priced, high-performance RapidBlue(TM) endovascular cooling system, which is expected to be launched in the U.S. market in the second quarter 2008. Using Euromed's marketing and sales force, sales of CoolBlue consoles and disposables are expected to begin in Europe this quarter, and sales of RapidBlue consoles and disposables are expected to begin next quarter.

(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

"We are pleased to have this distribution agreement with Euromed. They have a knowledgeable medical sales force with clinical support in our targeted markets, as well as extensive experience in selling temperature modulation products," stated Christopher J. Reinhard, Chairman and Chief Executive Officer of Cardium Therapeutics and InnerCool Therapies. "This new European partnership, along with our recent distribution agreement for Australia and New Zealand, are consistent with our strategy of a
'/>"/>

SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Teva Pharmaceuticals Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis
2. Pipeline for Lung Cancer Therapies is Focus of New MedPredict Report
3. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
4. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
5. Fate Therapeutics Created by Leading Stem Cell Scientists to Pursue New Approaches to Stem Cell Therapies
6. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
7. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
8. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
9. Tengion Announces European Orphan Drug Designation for Neo-Bladder Augment
10. DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
11. DaVita Announces Retirement of Former Chief Medical Officer Charles J. McAllister, M.D.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... On behalf of biotech client GenScript ... Goldman & Spitzer, P.A. (Wilentz) secured a significant jury ... in excess of $10 million. The jury determined that ... that it improperly hired one or more of GenScript,s ... judgment notwithstanding the verdict, a new trial, and remittitur. ...
(Date:2/26/2015)... JOLLA, Calif. , Feb. 26, 2015   ... a biopharmaceutical company leading the discovery and development of ... G. Xanthopoulos , Ph.D., President and Chief Executive Officer ... Cowen and Company 35 th Annual Healthcare Conference ... The conference is being held at the Boston Marriott ...
(Date:2/26/2015)... On behalf of biotech client ... Wilentz, Goldman & Spitzer, P.A. (Wilentz) secured a ... Genewiz Inc. in excess of $10 million. The jury ... secrets, and that it improperly hired one or more ... denying motions for judgment notwithstanding the verdict, a new ...
(Date:2/26/2015)... Pittsburgh, PA (PRWEB) February 26, 2015 ... March 9 -12, at the Ernest N. Morial ... 919 exhibitors (count as of February 19, 2015) ... community in industrial, academic, and government labs. The ... such as, but not limited to, analytical chemistry; ...
Breaking Biology Technology:Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Pittcon 2015 Announces Exposition Highlights 2
... UK,s National Physical Laboratory (NPL) is working to provide more ... nanotechnology which could lead to much more accurate devices ... Nobel Prize in 1986. It uses a nano-sized probe to ... finger reading Braille on an extremely small scale. The technique ...
... 20 Deloitte today released the 2010 Technology Fast ... media, telecommunications, life sciences and clean technology companies in ... fiscal year revenue growth from 2005 to 2009.  For ... on the Technology Fast 500™ than any other single ...
... Iowa, Oct. 20 Bio-Research Products announced today ... offerings a lower cost, industrial grade for application ... Dr. Bryce Cunningham, President, said that "there has ... and pharmaceutical markets which has prompted us to ...
Cached Biology Technology:Measuring the electrical properties of nano-crystals 2Deloitte Announces 2010 Technology Fast 500™ Rankings 2Deloitte Announces 2010 Technology Fast 500™ Rankings 3Deloitte Announces 2010 Technology Fast 500™ Rankings 4Bio-Research Products Introduces New Grade of Chloroperoxidase Enzyme for Industrial Applications 2
(Date:2/5/2015)... Calif. , Jan. 27, 2015 /PRNewswire/ ... provider of globally deployed, innovative test solutions ... announced the delivery of its TS-323 ... Space Systems Company (LMSSC). GENASYS is a ... demands of mission-critical applications that require performance ...
(Date:2/5/2015)... , Feb. 3, 2015 Despite a ... from industries such as consumer electronics, automotive, storage ... surface mount technology (SMT) screen printers. Innovations in ... control will push the adoption curve up. Meanwhile, ... steady as glue dispensers are indispensable in the ...
(Date:1/22/2015)... 13, 2015 Technology Showcase, Hall E -   EyeLock ... today announced it will showcase its EyeLock ID technology integrated ... Department of Energy,s Oak Ridge National Laboratory (ORNL) ... EyeLock,s iris identity authentication technology is being used to validate ...
Breaking Biology News(10 mins):Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3
... top of the marine food chain, albatrosses accumulate toxic ... bodies. A new study has found dramatic differences in ... forage in different areas of the North Pacific. Researchers ... increased in both species over the past ten years. ...
... When invaded by an infectious agent, for example, the ... and defeat the intruder. But when the biochemical processes ... turned on, inflammation can lead to adversity, including some ... closely studying the link between inflammatory processes and tumor ...
... a future in which each patient's tumor will act ... the cancer to obtain the best outcome. , ... should receive extra therapy after surgery - or whether ... does not even require surgery. Most patients with colorectal ...
Cached Biology News:Vegetables inhibit growth of prostate cancer in mice with human tumors 2Vegetables inhibit growth of prostate cancer in mice with human tumors 3Inflammation and drugs to control this activity studied in a variety of tumors sites 2Inflammation and drugs to control this activity studied in a variety of tumors sites 3Inflammation and drugs to control this activity studied in a variety of tumors sites 4Inflammation and drugs to control this activity studied in a variety of tumors sites 5Inflammation and drugs to control this activity studied in a variety of tumors sites 6Inflammation and drugs to control this activity studied in a variety of tumors sites 7Inflammation and drugs to control this activity studied in a variety of tumors sites 8Inflammation and drugs to control this activity studied in a variety of tumors sites 9AIDS-related cognitive impairment exists in two separate forms 2AIDS-related cognitive impairment exists in two separate forms 3AIDS-related cognitive impairment exists in two separate forms 4AIDS-related cognitive impairment exists in two separate forms 5AIDS-related cognitive impairment exists in two separate forms 6AIDS-related cognitive impairment exists in two separate forms 7
... Immunogen: Synthetic ... 22-37 SGHKSEEKREKMKRTL Antigen Family: ... signalling; Antigen Subfamily: ... signalling Recommended Storage: ...
V beta 5 Purified Anti-Human clone MH3-2, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
...
... The PROTEAN II xi 2-D system runs both ... first-dimension IEF tube gels can be separated in a ... onto the cooling core in much the same manner ... are running, the second-dimension slab gels may be cast ...
Biology Products: